Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urology Clear all
Completed Phase 3 Interventional Results available

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

NCT01223027
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Dovitinib, Sorafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 17, 2026, 4:03 PM EDT
Suspended No phase listed Observational

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

NCT05643690
View directory record Official record
Conditions
Bladder Cancer
Interventions
UriFind Bladder Cancer Assay
Diagnostic Test
Lead sponsor
AnchorDx Medical Co. Ltd. US
Industry
Eligibility
55 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 17, 2026, 4:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

NCT04179162
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer (NMIBC)
Interventions
Bacillus Calmette-Guérin (BCG), Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 17, 2026, 4:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 4:03 PM EDT
Active, not recruiting Not applicable Interventional

Perineal Massage for Pessary Examinations

NCT06416982
View directory record Official record
Conditions
Prolapse, Vaginal, Stress Urinary Incontinence, Pessaries, Pain
Interventions
Perineal massage
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 17, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional Results available

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

NCT01987596
View directory record Official record
Conditions
Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
1 Year to 25 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 17, 2026, 4:03 PM EDT
Terminated Phase 4 Interventional Results available

Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion

NCT03151746
View directory record Official record
Conditions
Anesthesia, Urethral Obstruction
Interventions
Placebo, Gabapentin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 17, 2026, 4:03 PM EDT
Completed No phase listed Observational

Bladder Cancer Patient-Reported Outcomes

NCT01090388
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Sep 17, 2026, 4:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

NCT05468697
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Belzutifan, Palbociclib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 4:03 PM EDT
Withdrawn Phase 4 Interventional

Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD

NCT04192110
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Diuretic initiation or augmentation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates

NCT01261910
View directory record Official record
Conditions
Kidney Transplant, Living-Donor Kidney Transplant, Chronic Kidney Disease, End-stage Renal Disease
Interventions
Intensive initial education
Behavioral
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury

NCT03503513
View directory record Official record
Conditions
Urinary Tract Infections, Spinal Cord Injuries, Spinal Cord Diseases, Neurogenic Bladder
Interventions
Gentamicin Sulfate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 17, 2026, 4:03 PM EDT
Completed No phase listed Observational

Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis

NCT02133313
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

NCT00749320
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Magnetic Resonance Imaging
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

NCT00007020
View directory record Official record
Conditions
Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis
Interventions
Cholic Acids
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 2Phase 3 Interventional

Communication During Hospitalization About Resuscitation Trial

NCT02984124
View directory record Official record
Conditions
Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy, Severe Functional Impairment, End Stage Renal Disease
Interventions
Informed Assent Discussion, Usual Care with Attention Control
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
65 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charleston, South Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 4:03 PM EDT
Not listed Phase 3 Interventional

SystemCHANGE: An Intervention for Medication Change in Adult Kidney Transplant Patients

NCT02416479
View directory record Official record
Conditions
Kidney Disease
Interventions
SystemCHANGE, Patient-education attention control
Behavioral
Lead sponsor
Cynthia Russell
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 17, 2026, 4:03 PM EDT
Not listed Phase 2 Interventional

Bucillamine Phase 2 Trial in Patients With Cystinuria

NCT02942420
View directory record Official record
Conditions
Cystinuria
Interventions
Bucillamine
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

NCT00465179
View directory record Official record
Conditions
Renal Cell Cancer, Kidney Cancer
Interventions
Sunitinib Malate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Home-Based Exercise to Treat Decreased Physical Function in Patients With Varying Levels of Kidney Function

NCT04745169
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
8 week home-based exercise program
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 17, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Oxidative Stress in Chronic Kidney Disease: Diet and Exercise

NCT01150851
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
caloric restriction, aerobic exercise
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Springfield, Massachusetts • Nashville, Tennessee • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 17, 2026, 4:03 PM EDT